drugset
Drugs / 10E8.4/iMab
last change Jul 2026 re-read 3 minutes ago

10E8.4/iMab

Monoclonal antibody

Developed for
HIV infectious disease
Investigated by
Bill and Melinda Gates Foundation · David Ho · International AIDS Vaccine Initiative · The Emmes Company, LLC

Trials 1

today NCT03875209 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03875209 Apr 2019 → Mar 2022 HIV infectious disease David Ho Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as 10E8.4/iMab ClinicalTrials.gov intervention name — accepted as the source's own label NCT03875209 ↗
Modality Monoclonal antibody “the bispecific monoclonal antibody 10E8.4/iMab” NCT03875209 ↗
Route Intravenous “10E8.4/iMab was administered intravenously (IV) or subcutaneously (SC).” PMID 42414619 ↗ Jul 2026
Route Subcutaneous “10E8.4/iMab was administered intravenously (IV) or subcutaneously (SC).” PMID 42414619 ↗ Jul 2026